Peripheral blood progenitor cells mobilized early at diagnosis in patients with chronic myelogenous leukemia contain very low amounts of BCR-ABL transcripts

TO THE EDITOR
In the last 8 years, in chronic myelogenous leukemia (CML) patients without a suitable donor for allografting, we demonstrated that it was possible to mobilize Ph-negative peripheral blood progenitor cells (PBPCs), more easily during the early chronic phase before interferon-␣ treatment.
1 Retroviral marking to tag the infused cells in the autografting procedure demonstrated that the residual leukemic cells present in the graft also contributed to the relapse.
2,3 Therefore, the reduction of the tumor burden in transplanted autologous PBPCs could be important for improving survival. In an attempt to monitor the amount of minimal residual disease at molecular level, we studied Ph-negative collections with a quantitative competitive RT-PCR (QC-RT-PCR) assay for BCR-ABL transcripts, essentially as described by Cross et al. 4, 5 In order to obtain a suitable competitor DNA, a 432-bp amplification product spanning the b3a2 BCR-ABL fusion region (from position −225 to 207 of the published sequence 6 ) was cloned in pCR-1 plasmid (Invitrogen, Leek, The Netherlands). The 222-bp fragment from AvaII-digested PBR322 was inserted in the AvaII site of the a2 exon (position 906). Known numbers of molecules of this construct were used in our assay as competitor DNA for cDNAs originated from endogenous BCR-ABL and ABL. Primers and amplification conditions were as described in Saglio et al. 7 The amount of BCR-ABL transcripts were reported g of total RNA. Total ABL transcripts were quantitated for every sample as internal control. The BCR-ABL/ABL ratio was calculated. We studied 17 patients: 13 patients in early chronic phase (ECP) and not pretreated with interferon and four patients in late chronic phase (LCP) highly pretreated with interferon. While the ECP patients had at least two Ph-negative collections, in LCP patients only the first leukapheresis resulted Ph-negative. For this reason we started our study by comparing the amount of the hybrid transcript, obtained by QC-RT-PCR, present in the first leukapheresis (Table 1) . LTC-IC were available for 12/13 patients in ECP and 2/4 LCP patients. The median of LTC-IC numbers for all these patients was 1.9 × 10 2 /kg (range 0-32.4) ( Table 1) . We found that in ECP mobilized patients, the numbers of BCR-ABL transcripts × g of RNA ranged from 50 to 150 (median 100) and BCR-ABL/ABL ratio was from 0.01 to 1% (median 0.2%). In the LCP patients BCR-ABL transcripts were from 150 to 1500 (median 1000) (P Ͻ 0.05); BCR-ABL/ABL ratio was from 0.1 to 3% (median 1%).
Although definitive conclusions require a more detailed analysis, comprehensive of the whole leukapheretic procedure for every patient and, possibly, a higher number of cases, it is evident that PBPCs from ECP patients have both lower amounts of BCR-ABL transcripts and more progenitor cells compared to PBPCs of LCP patients. These preliminary data seem to reinforce the concept that the best time to perform the mobilization procedure is shortly after diagnosis, not only because of the higher amount of diploid cells, but also because these progenitors are less contaminated by BCR-ABLpositive cells. Taken together, these molecular data clearly show that QC-RT-PCR is a reliable system to monitor residual disease in leukapheretic collections after intensive chemotherapy, giving us a tool to reduce, at the lowest level, the infused leukemic cells. The possible impact of this assay on autografting procedures will be established better when higher numbers of patients are studied. 
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Cytogenetic response induced by interferon alpha in the myeloproliferative disorder with eosinophilia, T cell lymphoma and the chromosomal translocation t(8;13)(p11;q12)
TO THE EDITOR A distinct biphenotypic hematological malignancy has been described in a subset of patients with a myeloproliferative disorder (MPD) characterized by myeloid hyperplasia and eosinophilia, a T cell lymphoblastic lymphoma (T-LBL), and a chromosomal translocation t(8;13)(p11;q12) in bone marrow (BM), and in some cases, also in lymph nodes (LN). 1,2 The description of other cases with similar morphological and clinical features with different translocations involving chromosome band 8p11 has led to the proposal of terming this entity as the '8p11 myeloproliferative syndrome'.
3 Moreover, a report of two cases with myeloid malignancy and a t(8;13) with a precursor T and B cell acute lymphoblastic leukemia (ALL) raises the question whether this cytogenetic abnormality results in a pluripotential stem cell capable of myeloid and lymphoid differentiation. 4, 5 At the molecular level, the t(8;13) has been recently characterized. The 8p11 breakpoint was found to be distinct from the t(8;16) and t(8;22) translocations, and therefore the MOZ gene was not rearranged. 5, 6 Despite all these patients being treated with diverse chemotherapy regimens, evolution to acute myeloid leukemia (AML) was rapid in most cases and thus optimal therapy for this entity is to be established. We report a patient with the t(8;13) syndrome who responded successfully to interferon alpha (IFN-␣) for 1 year. Subsequent allogeneic peripheral blood stem cell transplantation (PBSCT) was performed and currently she remains in complete remission 26 months after diagnosis.
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A 56-year-old female was referred for evaluation of a short history of weakness and leukocytosis. On physical examination she presented splenomegaly with no other remarkable features. A CBC showed RBC 8.23 × 10 6 /l, Hb 15.9 g/L, platelets 546 × 10 9 /l and WBC 85.9 × 10 9 /l with a differential count of 20% eosinophils and 6% basophils. LDH was 495 mU/ml and FAL 10. BM aspirate was markedly hypercellular with myeloid hyperplasia, 22% of eosinophils and 1% basophils. Cytogenetic analysis of BM identified a t(8;13)(p11;q12) in 25 of 25 metaphases karyotyped with additional cytogenetic abnormalities in 28% of cells. BCR/ABL-p210 rearrangement was not detected by RT-PCR. The patient was trated with cytarabine 10 mg/m 2 /day for 3 weeks and IFN-␣ 5 × 10 6 U/m 2 /day with a marked clinical and hematological response. Three months later, she developed massive generalized peripheral lymphadenopathy with WBC 7.0 × 10 9 /l and a normal BM film. Aspiration cytology and biopsy of a lymph node resected from the cervical area performed 1 week apart revealed a diffuse infiltration by a small lymphoid cell population with scant cytoplasm and round nuclei, with no myeloid infiltration. Immunophenotype analysis of lymphoid cells was: CD2 97%, CD3 10%, CD5 93%, CD4 91%, CD8 39%, CD13 1%, CD33 4%. In the lymph node aspiration cytology large immature lymphoid cells were seen and numerous mature eosinophils were scattered among the malignant cells. Therefore, a diagnosis of T cell lymphoma was made. TCR and IgH genes showed a germline configuration. IFN-␣ therapy was then continued and the lymphadenopathy resolved progressively in 2 months. A partial cytogenetic response was seen after 1 year of IFN-␣: only 70% of BM cells had a t(8;13), and moreover, secondary chromo-
